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Sir
The report by Taal et al (2001), on behalf of the Netherlands Adju-
vant Colorectal Cancer Project (NACCP), provides further evidence
of the beneﬁts of 5-ﬂuorouracil (5FU)-based regimes for the adju-
vant treatment of colorectal cancer (CRC). This multi-centred trial
entered a total of 1029 patients into control (surgery alone) and
treatment (surgery+12 months 5FU/Levamisole) arms. With a
median of almost 5 years follow-up, the results show survival
improvements of 8% and 12% for stage II and III patients, respec-
tively. Also of interest are the survival beneﬁts observed in the
tumour site, gender and age subgroups (Figure 5). Most of the
improved survival is attributable to colon cancer patients, while
female patients appear to derive approximately twice as much
beneﬁt as males. Although not cited by Taal et al (2001), we have
reported similar site and sex differences in the survival beneﬁt from
5FU/Leucovorin in a non-randomized, retrospective series of
Dukes’ C CRC patients (Elsaleh et al, 2000). We were led to these
observations by studies on the prognostic signiﬁcance of the micro-
satellite instability (MSI+) phenotype. By comparing the survival of
patients treated with or without chemotherapy, we noted an excel-
lent survival beneﬁt for MSI+ cases. Knowing that MSI+ tumours
are found almost exclusively in the proximal colon (Thibodeau et
al, 1993) and that sex-related differences had been reported for this
phenotype (Breivik et al, 1997), we were prompted to examine
various site and sex subgroups for the survival beneﬁt from 5FU.
In contrast to what is stated in the editorial accompanying the
NACCP study (Maughan, 2001), we found that the MSI+ group
could not account for the entire survival beneﬁt from 5FU (Elsaleh
et al, 2000). Although the frequency of MSI+ tumours in sporadic
CRC is similar to the degree of observed beneﬁt (approximately
10%), we also found that MSI-patients showed signiﬁcantly
improved survival with 5FU treatment. The molecular features
associated with response to 5FU remain to be fully characterized,
however both preclinical (Bunz et al, 1999) and clinical (Ahnen
et al, 1998; Elsaleh et al, 2001) studies have demonstrated a
requirement for normal TP53. It is therefore interesting to note
that ‘responsive’ MSI+ tumours nearly always have normal TP53,
whereas ‘non-responsive’ distal tumours are frequently TP53
mutant (Breivik et al, 1997; Elsaleh et al, 2001). Another insight
from the pioneering work of Breivik et al (1997), which also has
relevance to the NACCP ﬁndings, is that MSI+ tumours are most
frequent in younger male and older female CRC patients. It may
only be coincidental, but the youngest (560 years) and oldest
(465 years) patient subgroups in the study by Taal et al (2001)
derive more survival beneﬁt than the 60–65 year age group (Figure
5).
What are the implications of the NACCP study and what role, if
any, for molecular predictive factors in the management of CRC?
Clinicians and patients who were previously reticent about the
beneﬁts of 5FU treatment for stage II disease should now feel more
conﬁdent about its use, particularly for females and those with
proximal cancers. In contrast, there appears little survival beneﬁt
to be gained from the use of 5FU in males with rectal cancers.
These patients should be encouraged to enter trials for experimen-
tal drugs such as oxaliplatin and irinotecan, perhaps even as ﬁrst
line treatments. At this stage there seems little justiﬁcation for
the routine use of any of the known molecular predictive markers.
MSI+ is highly speciﬁc but lacks sensitivity for the detection of all
5FU responsive tumours (Elsaleh et al, 2000). TP53 is not sufﬁ-
ciently speciﬁc, since some patient groups with a mutation, most
notably females, still show an apparent survival beneﬁt from 5FU
(Elsaleh et al, 2001). Future studies may ﬁnd that other molecular
features such as DNA methylation or certain gene expression
patterns revealed by microarray analysis can provide sensitive and
speciﬁc predictive information for the survival beneﬁt from 5FU.
Until such time as these markers are incorporated into prospective
clinical trials in order to evaluate their true worth, the predictive
values of tumour site and sex should not be neglected. Both factors
are likely to be determinants of CRC subgroups that have different
molecular features and therefore different biological and clinical
properties, including the response to various adjuvant therapies.
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Iacopetta et al draw attention to a very important question: which
patients will beneﬁt the most from adjuvant therapy in colorectal
cancer (Maughan, 2001). Earlier, they reported on a retrospective,
non-randomised study of surgery with or without 5FU and Leva-
misole among 656 patients in Western-Australia, a treatment
interaction with gender, localisation of the tumour and microsatel-
lite instability (MSI) (Elsaleh et al, 2000). By extending their series,
up to 891 stage III colorectal cancer patients, similar results were
found with p53 in addition (Elsaleh et al, 2001). Chemotherapy
provided maximal beneﬁt in female patients and p53 normal
tumours.
In the Dutch NACCP trial a beneﬁcial effect of adjuvant treatment
was found in stage II and III (Taal et al, 2001). However, as the
NACCP trial was stopped early we did not reach enough statistical
power to perform reliable subgroup analysis. Female patients seemed
to beneﬁt more than male, but conﬁdence intervals were wide and the
result was not statistically signiﬁcant. Likewise adjuvant therapy
appeared not to be of beneﬁt in rectal cancer, but again, no signiﬁcant
interaction of treatment and tumour site was found and further
exploration is warranted.
Like others (Watanabe et al, 2001) we have explored the role
of molecular markers to select patients who might beneﬁt most
from adjuvant treatment. In a random sample of 116 patients
(64 male, 53 female) in either stage II (n=57) or stage III
(n=59), colonic cancer (n=82) as well as rectal cancer (n=34)
in fourteen patients (12%) MSI was found and in 43 cases
LOH chr18 (37%). MSI was almost exclusively found in colon
cancer (n=13) and only once in rectal cancer, whereas LOH
chr18 was present in two-thirds of colon cancer (n=28), but also
in rectal cancer patients (n=15). Difference in gender and stage
were not apparent. Disease speciﬁc survival revealed a superb
result for the MSI positive group (100% at 5 years); in the
LOH chr18 group survival was worse, but clearly better than
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Disease specific survival
Treatment At risk Events
0                  1                  2                  3                  4                  5
Years from registration
Numbers at risk
no RER/LOH      59          18
RER+                 14             0
LOH chr.18         43          16
LOH chr.18        43              41              39              35              26              19
RER+                 14              13              12              11              10                9
no RER/LOH     59                52              47              42              35              34 
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